EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The European medicines agency review of belzutifan (Welireg) for the treatment of adult patients with von Hippel–Lindau disease-associated tumors

Antonella Baron iD, Esther Broekman, Martijn van Gils, Elita Poplavska, Peter Mol, Ieva Saliete, Bruno Sepodes, Elias Pean

The Oncologist · 17.01.2026 · 31 (2)

DOI: 10.1093/oncolo/oyaf433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 08.01.2026. Verfasst von Antonella Baron und 7 weiteren Autor:innen. Beteiligte Einrichtung: European Medicines Agency, Amsterdam, HS 1083, the Netherlands. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, von Hippel-Lindau Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In February 2025, the European Commission granted approval for belzutifan (Welireg) as a treatment for certain von Hippel–Lindau (VHL) disease-associated tumors. This is the first medicinal product in Europe for pharmacological management of VHL, a rare, hereditary condition characterized by the development of multiple tumors across various organs. Belzutifan is an oral inhibitor of hypoxia-inducible factor-2α (HIF-2α), a protein involved in the pathogenesis of VHL-associated tumors. This approval, which is based on the results of the pivotal phase 2 clinical trial MK-6482-004 (LITESPARK-004) offers a therapeutic approach to managing certain VHL disease-associated tumors. This article describes the clinical data supporting belzutifan approval in the EU, focusing on the VHL disease indication and its mechanism of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Basic Helix-Loop-Helix Proteinsvon Hippel-Lindau DiseaseAdultHumansEndothelial PAS Domain-Containing Protein 1EuropeDrug ApprovalIndenes

Stichwörter der Autor:innen

European Medicines Agencybelzutifanrare tumorsvon Hippel Lindau

Substanzen

Basic Helix-Loop-Helix ProteinsbelzutifanEndothelial PAS Domain-Containing Protein 1Indenes

Autor:innen und Institutionen

  • European Medicines Agency, Amsterdam, HS 1083, the Netherlands.
  • Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, GZ 9713, the Netherlands.
  • Dutch Medicines Evaluation Board, Utrecht, AH 3531, the Netherlands.
  • Department of Applied Pharmacy, Faculty of Pharmacy and Institute of Public Health, Riga Stradiņš University, Riga, LV-1007, Latvia.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of GroningenGZ 9713, the Netherlands.
  • State Agency of Medicines of Latvia, LV-1003, Latvia.

ORCID-Profile: Antonella Baron

Zitieren

APA

Baron, A., Broekman, E., van Gils, M., Poplavska, E., Mol, P., Saliete, I., Sepodes, B., & Pean, E. (2026). The European medicines agency review of belzutifan (Welireg) for the treatment of adult patients with von Hippel–Lindau disease-associated tumors. The Oncologist, 31(2). https://doi.org/10.1093/oncolo/oyaf433

Vancouver

Baron A, Broekman E, van Gils M, Poplavska E, Mol P, Saliete I, et al. The European medicines agency review of belzutifan (Welireg) for the treatment of adult patients with von Hippel–Lindau disease-associated tumors. The Oncologist. 2026;31(2). doi:10.1093/oncolo/oyaf433

BibTeX
@article{Baron2026,
  author = {Baron, Antonella and Broekman, Esther and van Gils, Martijn and Poplavska, Elita and Mol, Peter and Saliete, Ieva and Sepodes, Bruno and Pean, Elias},
  title = {The European medicines agency review of belzutifan (Welireg) for the treatment of adult patients with von Hippel–Lindau disease-associated tumors},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {2},
  doi = {10.1093/oncolo/oyaf433}
}
Kostenlos starten →